Isturisa is commonly used to address the severe systemic consequences of endogenous hypercortisolemia (excessive cortisol levels) in adults with Cushing's syndrome, particularly when surgery is not an option or has not been curative. The medicine may assist with managing the symptoms of the disease, which is applied in addressing symptoms related to systemic imbalance.

The main conditions for which Isturisa is applied include Cushing's syndrome, Cushing's disease, and situations involving severe, persistent, or recurrent cortisol excess. The medication is used to manage symptoms related to heightened physiological activity, aiming for levels that support functional stability.

Isturisa supports the relief of complex symptoms that cluster due to chronic cortisol excess, which include metabolic abnormalities like high blood pressure and blood sugar dysregulation, and physical manifestations such as central weight gain and easy bruising. This contributes to easing the overall symptom load.

Isturisa provides a relevant non-surgical option for patients in specialized scenarios, such as when they are not candidates for surgery or experience persistent disease. It provides a non-surgical pathway that supports the patient during difficult episodes by easing distress.

Quick Fact: Relief for Systemic Imbalance
Isturisa is applied to ease symptoms related to systemic imbalance, which supports general well-being during symptomatic phases and contributes to easing the overall symptom load.

Regulatory References

1. European Medicines Agency (EMA) overview

The eligibility for using Isturisa (osilodrostat) is strictly defined by regulatory documentation concerning patient population, age, organ function, and reproductive status.

Approved and Contraindicated Populations

Eligibility Scope	Official Regulatory Status
Approved Population	Adult patients (18 years and older) with endogenous hypercortisolemia (Cushing’s syndrome) for whom surgery is not an option or has not been curative.
Contraindicated Population	Patients with known hypersensitivity to osilodrostat or any excipients must not use the medicine.

Conditional Use and Restrictions

Age-Related Rules: The medicine's safety and effectiveness have not been established in pediatric patients (under 18 years). Use in older adults (65 and over) is permitted but must be approached with caution due to limited data.

Organ Function and Comorbidities: Use is restricted by hepatic impairment (liver disease); for example, patients with moderate or severe impairment have specific requirements for treatment initiation. Before starting treatment, electrolyte abnormalities such as hypokalemia or hypomagnesemia must be corrected. Caution is also advised when treating patients with pre-existing risk factors for QT prolongation, such as congenital long QT syndrome or significant cardiovascular disease.

Pregnancy and Lactation: Isturisa should not be used during pregnancy. Women of childbearing potential must use effective contraception during treatment and for at least one week after stopping. Breastfeeding is not recommended during therapy.

Interactions with other medicines and products

Isturisa (osilodrostat) interaction patterns are defined by its involvement with drug-metabolizing enzymes and its potential for effects on cardiac electrical activity, as stated in regulatory labels.

---

Pharmacokinetic Interactions

Isturisa is both a substrate for and an inhibitor of Cytochrome P450 (CYP) enzymes, leading to altered blood levels of itself or other medicines.

Interaction Type	Interacting Medicines (Examples)	Official Outcome	Restriction/Classification
Exposure Increasing	Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin)	Increases osilodrostat plasma exposure.	Clinically significant; requires dose modification.
Exposure Decreasing	Strong CYP3A4 and CYP2B6 inducers (e.g., rifampin, carbamazepine)	Decreases osilodrostat plasma exposure.	Clinically significant; requires dose modification.
As an Inhibitor	CYP1A2 substrates (e.g., theophylline, tizanidine); CYP2C19 substrates (e.g., S-mephenytoin)	Increases exposure of co-administered narrow therapeutic index substrates.	Use with caution.

---

Pharmacodynamic and Other Constraints

• QTc Prolongation Risk: Co-administration with other medicinal products known to prolong the QTc interval on the electrocardiogram is classified as requiring caution due to an additive effect.
• Contraindicated Combination: Co-administration with cisapride is formally prohibited due to the risk of increased cisapride exposure, which enhances QTc prolongation risk.
• Population-Specific Note: Increased osilodrostat exposure is documented in patients with moderate to severe hepatic impairment, which is a condition requiring altered drug management as defined in prescribing information.
• Food Interaction: Regulatory documentation states that food does not affect the pharmacokinetics of osilodrostat to a clinically significant extent.

Targeted Inhibition of Cortisol Production

The drug functions as an enzyme inhibitor, primarily targeting 11beta-hydroxylase (CYP11B1), which catalyzes the final stage of cortisol creation in the adrenal cortex. By competitively binding to and blocking this enzyme, the drug prevents the conversion of precursor compounds into active cortisol, initiating a cascade that leads to a systemic reduction in the body's circulating cortisol concentration.

Modulation of Steroid Precursors and Feedback

The enzymatic blockade causes the accumulation of steroid precursors, most notably 11-deoxycorticosterone (DOC), which itself has mineralocorticoid-like activity and interacts with the mineralocorticoid receptor. Additionally, the drop in cortisol releases the natural negative feedback on the Hypothalamic-Pituitary-Adrenal (HPA) axis, resulting in a compensatory increase in ACTH that challenges the mechanism's inhibitory effect.

How Isturisa is Used: Administration Guidelines

Isturisa (osilodrostat) is used via oral administration as a film-coated tablet in 1 mg, 5 mg, and 10 mg strengths. The tablets can be taken with or without food.

Standard Dosing and Titration

Treatment typically begins with a starting dose of 2 mg taken twice daily (BID). The dosage is highly individualized and is adjusted (titrated) based on the patient's urinary free cortisol levels and clinical status.

Adjustments are made gradually, usually by 1 mg to 2 mg twice daily, and generally occur no more frequently than every two weeks. The dosing process continues until cortisol levels are normalized or within the target range. The maximum recommended dose is 30 mg twice daily (60 mg total daily dose).

Isturisa is intended for long-term use for the management of endogenous hypercortisolism. If a dose is missed, patients should take the next prescribed dose at the usual time, and the next dose should not be doubled.

Population-Specific Use

Instructions include specific modifications for certain patient populations:

• Hepatic Impairment: The recommended starting dose is lower for patients with moderate hepatic impairment (1 mg twice daily) and severe hepatic impairment (1 mg once daily in the evening).
• Asian Ancestry: The initial dose is 1 mg twice daily.
• Renal Impairment: No dose adjustment is required for patients with renal impairment.
• Pediatric Use: Safety and effectiveness have not been established in children.

The initial phase of treatment requires supervision by a physician with expertise in endocrinology to manage the highly individualized titration and monitoring process.

Evidence for Use in Endogenous Hypercortisolism

Research for Isturisa primarily explored its use in adults with Cushing's disease, a condition involving high cortisol levels (endogenous hypercortisolism). The main evidence is drawn from multi-center randomized controlled trials (RCTs) that included patients who were not candidates for surgery or who experienced a recurrence of their condition. These studies monitored the mean urinary free cortisol (mUFC), a key hormonal measure, along with changes in physical manifestations of the disease, such as body weight. The findings describe patterns observed in these trials, with studies reporting measurements related to the percentage of patients achieving normal mUFC levels during the short, randomized comparison phase.

Long-Term Research and Evidence Gaps

Clinical trials included open-label extension studies where patients were observed for up to two years or more to gather data on the sustained effects of treatment. This data suggests patterns related to changes in cortisol levels over time. However, the long-term evolution of cortisol levels and the impact on disease progression for many years is not fully established.

Research also notes limitations typical of studies for rare diseases. The total sample sizes were modest, and the period during which Isturisa was directly compared to a placebo was short (typically 8 to 12 weeks). Consequently, limited comparative data exist for changes in secondary clinical features over a prolonged duration. Additionally, data for specific patient groups, such as older adults (over 65 years) and those with impaired liver or kidney function, remain insufficient to draw broad conclusions, and the primary research focused heavily on Cushing's disease, leaving data for other causes of Cushing's syndrome still emerging.

Common questions about Isturisa (FAQ)

Q: Does Isturisa help with weight gain?

A: Official studies of Isturisa in patients with Cushing’s disease examined changes in body weight and Body Mass Index (BMI). Clinical data indicates that a decrease in body weight was generally reported during trials that monitored cortisol normalization.

Q: Can Isturisa be used by people with kidney issues?

A: Official regulatory guidelines state that no dose adjustment is required for patients with renal impairment (kidney issues). However, official documents advise that caution is needed when healthcare providers interpret urinary free cortisol (UFC) levels in patients who have moderate to severe kidney impairment.

Q: Can Isturisa affect my blood sugar?

A: Isturisa is designed to lower cortisol levels. Official safety information notes that this significant reduction can sometimes lead to conditions like hypoglycemia (low blood sugar levels). Official safety information notes that monitoring of electrolyte levels and for hypoglycemia is a required part of the treatment process.

Q: Is Isturisa safe to take if I have diabetes?

A: Official product information notes that Isturisa can potentially lead to hypoglycemia (low blood sugar) due to the reduction of cortisol. Because of this, patients are monitored closely for blood sugar changes according to official guidelines. Regulatory documents state that any pre-existing electrolyte abnormalities are required to be corrected before starting treatment.

Q: How quickly does Isturisa start to work?

A: Clinical trial data indicated that the median time (the middle value) observed for patients to achieve a normal range of urinary free cortisol levels was approximately 35 days. This measure of effectiveness is used to guide dosage adjustments during treatment.

Q: Does Isturisa cause problems with sleep?

A: Yes, official drug safety documents list sleep disorders as a reported adverse reaction observed in clinical trials. This category includes issues such as insomnia (difficulty sleeping) or somnolence (feeling unusually sleepy or drowsy).

Q: Are there any foods or drinks I need to avoid while on Isturisa?

A: Regulatory documentation states that food does not significantly affect the way the medicine works. Official information provides specific warnings regarding medicines that interact with drug-metabolizing enzymes (CYP450) and those that may affect the QTc interval.

Q: Does Isturisa interact with supplements like vitamins or herbal remedies?

A: The drug is known to interact with specific liver enzymes (CYP450 enzymes) used to process medicines and other substances. Therefore, official labeling notes that other substances, including herbal remedies or supplements that affect these same enzymes, may result in altered levels of the drug or the co-administered substance.

Q: Does Isturisa make birth control pills less effective?

A: Regulatory documents state that women of childbearing potential are required to use effective contraception while taking Isturisa and for at least one week after discontinuation. The official information recommends that if hormonal contraceptives other than the oral combination of ethinyl estradiol and levonorgestrel are used, an additional barrier method should be used.

Q: Can men and women take Isturisa?

A: Yes, Isturisa is officially indicated for the treatment of endogenous hypercortisolemia in all adults who have Cushing’s syndrome and for whom surgery is not an option or has not been curative. Specific guidance is noted for women related to pregnancy and breastfeeding status.

Q: Does the dose of Isturisa change based on my weight?

A: Official dosing guidelines state that the dosage is highly individualized for each patient. Adjustments are based on a patient's urinary free cortisol levels and overall clinical status, and the drug’s effectiveness is not specified to be based on body weight.

Q: What happens when I stop taking Isturisa?

A: Regulatory information indicates that discontinuation may lead to a return of the original symptoms of hypercortisolism. Additionally, official documents note that the significant lowering of cortisol levels may persist after the medicine is discontinued, which necessitates ongoing monitoring of hormonal levels.

Q: What is the typical range of dosage described in official materials?

A: Official documents define a starting dose and a maximum recommended dose. Clinical evidence indicates that the usual maintenance dosage observed in studies fell within the range of 2 mg to 7 mg twice daily for most patients.

Q: Are there different brand names for the same medicine as Isturisa?

A: The active ingredient in Isturisa is osilodrostat. Isturisa is currently the only approved brand name for the active ingredient osilodrostat in the United States and Europe, as of the time of its regulatory approval.

Q: Is Isturisa used for any condition other than Cushing's disease?

A: Isturisa is specifically indicated for the treatment of endogenous hypercortisolemia in adults with Cushing’s syndrome. This condition is generally characterized by high cortisol levels, regardless of the underlying cause.

Q: Does Isturisa have a Black Box Warning?

A: The official U.S. Food and Drug Administration (FDA) labeling for Isturisa does not contain a Black Box Warning.

Q: How often do I need to see the doctor while taking Isturisa?

A: Official documents generally recommend that cortisol levels are monitored at least every 1 to 2 months once the maintenance dosage is finalized. The exact frequency of follow-up visits will be determined by the treating healthcare provider based on a patient's clinical status.

Q: Is Isturisa a drug that requires a risk evaluation and mitigation strategy (REMS)?

A: According to the U.S. Food and Drug Administration (FDA), Isturisa does not require a formal REMS (Risk Evaluation and Mitigation Strategy) program. A REMS program is required for certain medications with serious safety concerns.

Q: How long has Isturisa been approved for use?

A: Isturisa (osilodrostat) was approved by the U.S. Food and Drug Administration (FDA) in March 2020 and by the European Medicines Agency (EMA) in January 2020, making it a relatively new treatment option.

Q: Can Isturisa cause mood changes or depression?

A: Yes, official drug information lists mental depression and mood changes as reported side effects observed in clinical trials. Anxiety is also noted among the central nervous system side effects.

Q: Does Isturisa have any warnings about alcohol consumption?

A: Regulatory documents do not list a specific formal contraindication for alcohol consumption. Official documents note a caution regarding potential effects on the QTc interval (an electrical measure of the heart) and interactions with drug-metabolizing enzymes, which should be considered.

Isturisa (osilodrostat) tablets must be stored according to official regulatory specifications to maintain product integrity and safety.

Official Storage and Disposal Requirements

Item	Regulatory Constraint
Temperature Requirements	Store at 20 C to 25 C (68 F to 77 F) (Controlled Room Temperature); do not store above 25 C.
Protection and Packaging	Store in the original package in order to protect from moisture.
Child Safety	Keep the medicine out of the sight and reach of children.
Disposal	Dispose of any unused medicine or waste material in accordance with local requirements.

These constraints ensure the active ingredient, osilodrostat, remains stable for its labeled shelf life. The labeling explicitly mandates storage at room temperature, protection from moisture, and adherence to child-safety protocols. There are no special requirements listed for disposal beyond following local waste regulations.